Ayman Abouzayed
Overview
Explore the profile of Ayman Abouzayed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang J, Rinne S, Yin W, Leitao C, Bjorklund E, Abouzayed A, et al.
ACS Pharmacol Transl Sci
. 2024 Oct;
7(10):3228-3240.
PMID: 39416966
The outcome of clinical trials evaluating drugs targeting the human epidermal growth factor receptor 3 (HER3) has been poor, with primary concerns related to lack of efficacy. HER3 is considered...
2.
Nagy A, Abouzayed A, Kanellopoulos P, Landmark F, Bezverkhniaia E, Tolmachev V, et al.
ACS Omega
. 2024 Sep;
9(34):36122-36133.
PMID: 39220525
Targeting the gastrin-releasing peptide receptor (GRPR) with the bombesin analogue RM26, a 9 aa peptide, has been a promising strategy for cancer theranostics, with recent success in radionuclide imaging of...
3.
Zhang J, Bodenko V, Larkina M, Bezverkhniaia E, Xu T, Liao Y, et al.
J Control Release
. 2024 May;
370:468-478.
PMID: 38697314
A critical parameter during the development of protein therapeutics is to endow them with suitable pharmacokinetic and pharmacodynamic properties. Small protein drugs are quickly eliminated by kidney filtration, and in...
4.
Kanellopoulos P, Bezverkhniaia E, Abouzayed A, Rosenstrom U, Tolmachev V, Orlova A
ACS Omega
. 2024 Apr;
9(16):18608-18616.
PMID: 38680331
Gastrin releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PC-3) and can be used for diagnostic purposes. We herein present the design and preclinical evaluation of two novel NOTA/NODAGA-containing...
5.
Obeid K, Kanellopoulos P, Abouzayed A, Mattsson A, Tolmachev V, Nock B, et al.
Pharmaceutics
. 2024 Apr;
16(4).
PMID: 38675174
Gastrin-releasing peptide receptor (GRPR)-antagonists have served as motifs in the development of theranostic radioligands for prostate cancer. Our efforts have been focused on the development of radiolabeled RM26 (H-DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH) analogs,...
6.
Kanellopoulos P, Mattsson A, Abouzayed A, Obeid K, Nock B, Tolmachev V, et al.
EJNMMI Radiopharm Chem
. 2024 Feb;
9(1):13.
PMID: 38366299
Background: The gastrin-releasing peptide receptor (GRPR) has been extensively studied as a biomolecular target for peptide-based radiotheranostics. However, the lack of metabolic stability and the rapid clearance of peptide radioligands,...
7.
Bezverkhniaia E, Kanellopoulos P, Abouzayed A, Larkina M, Oroujeni M, Vorobyeva A, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139219
Radionuclide imaging using radiolabeled inhibitors of prostate-specific membrane antigen (PSMA) can be used for the staging of prostate cancer. Previously, we optimized the Glu-urea-Lys binding moiety using a linker structure...
8.
Abouzayed A, Seitova K, Lundmark F, Bodenko V, Oroujeni M, Tolmachev V, et al.
Front Oncol
. 2023 Oct;
13:1221103.
PMID: 37829345
Introduction: Prostate specific membrane antigen (PSMA), highly expressed in metastatic castration-resistant prostate cancer (mCRPC), is an established therapeutic target. Theranostic PSMA-targeting agents are widely used in patient management and has...
9.
Abouzayed A, Kanellopoulos P, Gorislav A, Tolmachev V, Maina T, Nock B, et al.
Biomolecules
. 2023 Jul;
13(7).
PMID: 37509170
Radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists have shown great promise for the theranostics of prostate cancer; however, their suboptimal metabolic stability leaves room for improvements. It was recently shown that...
10.
Abouzayed A, Zedan W, Altai M, Strand J, Orbom A
Am J Nucl Med Mol Imaging
. 2023 Jul;
13(3):107-117.
PMID: 37457328
One novel option for treating metastatic castration resistant prostate cancer is radionuclide therapy targeting prostate-specific membrane antigen (PSMA), e.g. [Lu]Lu-PSMA-617. Overexpression of HER2 has been found in 80% of metastatic...